Predictors of Insulin-Like Growth Factor-I Responses to Growth Hormone Replacement in Young Adults with Growth Hormone Deficiency

被引:6
作者
Thankamony, Ajay [1 ]
Capalbo, Donatella [1 ]
Jonsson, Peter J. [4 ]
Simpson, Helen L. [2 ]
Dunger, David B. [1 ,3 ]
机构
[1] Univ Cambridge, Dept Paediat, Cambridge, England
[2] Cambridge Univ Hosp Fdn Trust, Inst Metab Sci, Wolfson Diabet & Endocrine Clin, Cambridge, England
[3] Cambridge Comprehens Biomed Res Ctr, Natl Inst Hlth Res, Cambridge, England
[4] Pfizer Endocrine Care, KIMS Med Outcomes, Sollentuna, Sweden
来源
HORMONE RESEARCH IN PAEDIATRICS | 2016年 / 85卷 / 06期
关键词
Growth hormone deficiency; IGF-I response; Somatic maturation; Transition; GH dose titration; SEVERE GH DEFICIENCY; BODY-COMPOSITION; ENDOCRINE-SOCIETY; LINEAR GROWTH; TRANSITION; THERAPY; CHILDHOOD; 2-YEAR; AGE; MULTICENTER;
D O I
10.1159/000445832
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: Physiological growth hormone (GH) secretion and insulin-like growth factor-I (IGF-I) levels are greater in young compared to older adults. We evaluated IGF-I levels and predictors of IGF-I responses in young adults on GH replacement. Design: From the KIMS database, 310 young adults (age 15-26 years) with severe GH deficiency related to childhood-onset disease and commenced on 'adult GH replacement' were identified. 'IGF-I responses' were estimated from first-year increments in IGF-I standard deviation scores (SDS) and adjusted for GH dose. Body composition was assessed by bioimpedance in 143 patients. Results: IGF-I levels increased markedly from baseline to 1 year of replacement (-3.75 +/- 1.94 vs. -1.36 +/- 1.86 SDS, p < 0.0001), but remained low compared to normative data despite dose titration. In multivariate models, IGF-I responses were positively associated with age [B (SE) SDS/(mg/m(2)); 0.52 (0.15), p = 0.0007] and BMI SDS [1.06 (0.25), p < 0.0001] and inversely associated with female gender [-4.45 (0.79), p < 0.0001] and baseline IGF-I SDS [-1.44 (0.20), p < 0.0001]. IGF-I responses were positively associated with first-year increases in lean body mass (r = 0.19, p = 0.003) and haemoglobin A1c (r = 0.15, p = 0.031). Conclusions: Low IGF-I levels in young adults on treatment may reflect suboptimal GH replacement. Identification of predictors for IGF-I responses could lead to a more appropriate replacement strategy. Association between IGF-I responses and lean body mass suggests that maintaining age-appropriate IGF-I levels is important during therapy. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:379 / 388
页数:10
相关论文
共 45 条
[1]   Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients [J].
Attanasio, AF ;
Shavrikova, E ;
Blum, WF ;
Cromer, M ;
Child, CJ ;
Paskova, M ;
Lebl, J ;
Chipman, JJ ;
Shalet, SM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (10) :4857-4862
[2]   Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults [J].
Barbosa, Edna J. L. ;
Koranyi, Josef ;
Filipsson, Helena ;
Bengtsson, Bengt-Ake ;
Boguszewski, Cesar Luiz ;
Johannsson, Gudmundur .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2010, 162 (05) :869-878
[3]   The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults [J].
Bengtsson, BÅ ;
Abs, R ;
Bennmarker, H ;
Monson, JP ;
Feldt-Rasmussen, U ;
Hernberg-Ståhl, E ;
Westberg, B ;
Wilton, P ;
Wüster, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) :3929-3935
[4]   Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system:: Results from a multicenter study [J].
Brabant, G ;
von zur Mühlen, A ;
Wüster, C ;
Ranke, MB ;
Kratzsch, J ;
Kiess, W ;
Ketelslegers, JM ;
Wilhelmsen, L ;
Hulthén, L ;
Saller, B ;
Mattsson, A ;
Wilde, J ;
Schemer, R ;
Kann, P .
HORMONE RESEARCH, 2003, 60 (02) :53-60
[5]   Clinical implications of residual growth hormone (GH) response to provocative testing in adults with severe GH deficiency [J].
Brabant, Georg ;
Rasmussen, Ase Krogh ;
Biller, Beverly M. K. ;
Buchfelder, Michael ;
Feldt-Rasmussen, Ulla ;
Forssmann, Kristin ;
Jonsson, Bjorn ;
Koltowska-Haggstrom, Maria ;
Maiter, Dominique ;
Saller, Bernhard ;
Toogood, Andy .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (07) :2604-2609
[6]   Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth [J].
Carroll, PV ;
Drake, WM ;
Maher, KT ;
Metcalfe, K ;
Shaw, NJ ;
Dunger, DB ;
Cheetham, TD ;
Camacho-Hübner, C ;
Savage, MO ;
Monson, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (08) :3890-3895
[7]   Consensus statement on the management of the GH-treated adolescent in the transition to adult care [J].
Clayton, PE ;
Cuneo, RC ;
Juul, A ;
Monson, JP ;
Shalet, SM ;
Tauber, M .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (02) :165-170
[8]   Growth hormone replacement throughout life: Insights into age-related responses to treatment [J].
Clayton, Peter ;
Gleeson, Helena ;
Monson, John ;
Popovic, Vera ;
Shalet, Stephen M. ;
Christiansen, J. Sandahl .
GROWTH HORMONE & IGF RESEARCH, 2007, 17 (05) :369-382
[9]   Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: Implications for efficacy and safety [J].
Cohen, P ;
Bright, GM ;
Rogol, AD ;
Kappelgaard, AM ;
Rosenfeld, RG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :90-98
[10]   The cardiovascular risk of GH-defficient adolescents [J].
Colao, A ;
Di Somma, C ;
Salerno, M ;
Spinelli, L ;
Orio, F ;
Lombardi, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) :3650-3655